2024-05-13 15:14:00
Created in 2018 at the initiative of Emmanuel Macron, the Choose France summit brings together numerous foreign investors each year to praise the attractiveness of France. On the occasion of the 7th edition, which was held on May 13, 2024 in Versailles, under the aegis of Emmanuel Macron, several pharmaceutical groups committed to investing more than an additional billion euros in the sector. health in France.
Among them, the American giant Pfizer plans more than 500 million euros of additional investments in France over the next five years to develop R&D, particularly in the fields of oncology and hematology, as well as the production of drugs. “ Our intention is to significantly increase the share of French sites in our major international clinical studies in oncology. “, declared Reda Guiha, president of Pfizer France. These investments are in addition to those announced during the Choose France 2022 and 2023 editions and bring the commitment of the American laboratory, which does not have its own factory in France, to more than 1.5 billion euros. .
The pharmaceutical group AstraZeneca also intends to invest on French soil. The British company has committed to allocate 388 million dollars (or more than 360 million euros) to the decarbonization and extension of its Dunkirk (North) site specializing in aerosol medicines, with the key being the creation of around a hundred additional jobs. This brings the investments made by the group in France since 2020 to more than 2 billion euros. Another British laboratory to take part in Choose France 2024: GSK. The group will devote an additional 140 million euros to modernize, digitalize and decarbonize its three French production sites: Evreux (Eure), Saint-Amand-les-Eaux (Nord) and Mayenne (Mayenne).
The American company AbbVie has also decided to strengthen its industrial footprint in France via an investment of 36 million euros to develop its R&D and production activities in aesthetic medicine on its Annecy-Pringy site (Haute- Savoy). Furthermore, the Swiss laboratory Novartis took advantage of this summit to announce its intention to invest 28 million euros to create a production unit dedicated to supplying the French market with radiotherapies. A decision should result in the creation of 25 jobs.
Finally, other foreign laboratories also wanted to add their stone to the building. The Italians Chiesi and Zambon (fine chemicals) respectively plan 10 million euros of additional investment for the creation of around a hundred jobs on the Chaussée Saint-Victor site (Loir-et-Cher), and 86 million additional euros for the modernization and increase in production capacities of the Avrillé site (Maine-et-Loire), with 90 new jobs created. The American Kenvue, former consumer health division of J&J, formalizes a budget of 10.7 million euros to extend its production lines at its Val-de-Reuil (Eure) factory, leading to the creation of 45 direct jobs. Finally, the Moroccan Laprophan announces the creation of Europhan, following the purchase of the Monts (Indre-et-Loire) manufacturing site from Recipharm last March and thus marks its introduction to the European pharmaceutical market.
« France’s overall competitiveness and attractiveness have strengthened and this is good news, but in the field of health industries, it can and must still improve. », Commented the union of pharmaceutical companies (Leem) in a forum.
1715619825
#foreign #pharmaceutical #companies #invest #France